Search PubMed⌕ Search

Biomedical subjects

J Otto

Publications and source records attributed to J Otto.

177 records · Page 10Linked to original sources
PubMedDate not supplied

Primary lung sarcomas: long survivors obtained with iterative complete surgery.

Primary lung sarcomas are uncommon histologic types of primary lung cancer and presents a wide spectrum of clinical behaviour. Nine patients treated at Antoine Lacassagne Cancer Center between 1982 and 1995 were studied. The median age was 63 years (range, 35-73 years) and the most common histologic types were malignant fibrous histiocytoma (four) and leiomyosarcoma (three). All of them underwent surgery, six patients had a complete surgery and three patients incomplete resections. The median overall survival for all patients was 36 months. In the subgroup of patients with initial complete resection, the median survival was significantly longer (47 months) than in the subgroup of patients with incomplete resection (6 months) (P<0.05, log-rank test). Moreover, two patients had a second complete resection for ipsilateral lung relapse and were long survivors (overall survival of 58 and 83 months, respectively). The ability to achieve a complete second surgery stress the possible benefit of an early detection of local recurrence. Because no specific symptom was linked with the local relapse, a systematic CT scan every 2 or 3 months could be required.

Adult↗
PubMedDate not supplied

A multivariate analysis for predicting cisplatin-induced delayed emesis.

The present study was designed to address the question of the early identification of patients at risk of developing cisplatin (CP)-related delayed emesis. This study included demographic, clinical, biological and pharmacological data and was conducted on 110 consecutive patients treated by CP-based chemotherapy. A previously validated single-point CP pharmacokinetic evaluation was performed in all patients. A total of 110 cycles was analyzed. Delayed vomiting (i.e., occurring between day 3 and day 7 following CP administration) was observed in 36.4% of cycles. Among the tested variables, the occurrence of delayed emesis was significantly related to elevated ultrafilterable (UF) platinum concentration (measured 16 h after the end of CP administration) and to low plasma magnesium concentration (measured 48 h before CP administration). Risk-thresholds for delayed emesis were established for UF platinum and magnesemia, at 60 ng/ml and 58 mmol/l, respectively. In the sub-group of patients with magnesemia determination, this later parameter was the only significant predictor of delayed emesis. Gender, cycle number, primary cancer location and age were not associated with the risk of developing delayed emesis. The ability to select patients at risk of delayed vomiting may offer a practical means of targeting administration of specific treatments.

Adult↗
PubMedDate not supplied

Electric stimulation in chronic headaches.

Therapeutic electric stimulation in cases of chronic headaches was carried out in 150 patients. Migraine was diagnosed in 40 cases, common vasomotor headache in 63, cervical migraine in 24, Horton's neuralgia in 5 and complex headaches in 18 cases. The results are reported here, which were best in the cervical migraine syndrome, while in the typical migraine they were the least successful.

Adult↗
PubMedDate not supplied

[Guillain-Barré syndrome and non-Hodgkin's lymphoma. Report of one case and review of literature].

Patients with lymphoma frequently develop neurologic abnormalities mainly due to nervous system infiltration but also direct drug toxicity. Moreover Guillain-Barré syndrome (GBS) remains a possible neuropathy, rarely described in non-Hodgkin's lymphoma. We describe a case of GBS in a patient with non-Hodgkin's high grade lymphoma. A 74-year old man with a newly diagnosed stage I high-grade lymphoma (precursor B-cell Burkitt like type according to the R.E.A.L. Classification) develop flaccid quadriparesis, 7 days after the end of the third course of CHOP treatment. The clinical course and neurological examination were consistent with GBS. The patient was in tumoral complete response. Despite appropriate treatment and a transfer in a reanimation unit, the patient died 3 days after the beginning of neurologic symptoms. The low number of cases described in the international literature doesn't permit to understand the association of this neurologic disease with non-Hodgkin's lymphoma. Collecting more data could lead interesting information to know the place of malignant hematological disease in the natural history of GBS.

Aged↗
PubMedDate not supplied

The "additional subunit" CF0II of the photosynthetic ATP-synthase and the thylakoid polypeptide, binding ferredoxin NADP reductase: are they different?

Evidence is presented to support the notion that the 16 kDa thylakoid polypeptide, called CF0II, is an essential subunit of the photosynthetic ATP-synthase complex CF0CF1: It is co-isolated with the other subunits of CF0CF1 in preparations either using octylglucoside/cholate or Triton X-100. It is co-precipitated by antibodies together with the other CF0CF1 subunits. It is immunochemically not related to thylakoid polypeptides of higher molecular weight nor to some thylakoid polypeptides with similar apparent molecular weight between 16 and 18 kDa: CF1 epsilon, CF0I, subunit IV of the b6f complex, the 16.5 kDa peripheral polypeptide of the oxygen evolving complex of PS II, and the intrinsic ferredoxin NADP reductase binding protein. The N-terminal amino acid sequences of CF0II and the reductase binding protein is determined by Edman degradation and compared: The two sequences are different and not identical to other characterized thylakoid polypeptides. Monospecific antibodies against CF0II inhibit rebinding of CF1 to EDTA treated thylakoid membranes, H+ efflux from EDTA treated membranes and cyclic photophosphorylation. Thus the additional polypeptide CF0II qualifies for a functional subunit of the photosynthetic ATP-synthase.

Amino Acid Sequence↗
PubMedDate not supplied

Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors.

STUDY OBJECTIVE: To evaluate the usefulness of biologic and pharmacologic parameters for early identification of cisplatin-induced renal dysfunction. DESIGN: Prospective evaluation of 62 consecutively admitted patients with cancer. SETTING: Cancer center. PATIENTS: Sixty-two consecutive patients with cancer (52 men, 10 women; mean age 61.9 yrs). INTERVENTIONS: Patients received cisplatin as a single short intravenous infusion every 3 weeks. One hundred twenty-one cycles were analyzed. The dosage in the first cycle ranged between 61 and 105 mg/m2 (mean 84 mg/m2). All patients received a standard hydration protocol. MEASUREMENTS AND MAIN RESULTS: Renal function was evaluated for each cycle before treatment (day 0) and before next cycle (day 21) based on the estimated creatinine clearance (Clcr). For each cycle, the weighted relative decrease (WD) of Clcr was calculated (WDClcr = 100 x [Clcr (day 0) - Clcr (day 21)]/[Clcr (day 0)](2). Total and ultrafilterable (UF) platinum were measured as a single-sample assay taken 16 hours after the end of cisplatin administration. The mean WDClcr was 0.07 min/100 ml (range -1.0 to +1.7 min/100 ml). The intensity of renal dysfunction evaluated by WDClcr was independent of cisplatin dosage, age, sex, body surface area, initial Clcr, and cycle number. Of interest, total and UF platinum concentrations were significantly correlated to WDClcr: the higher the platinum concentration, the greater the intensity of renal dysfunction. In stepwise regression analysis, UF platinum concentration was the only selected factor. The best prediction of UF platinum was obtained by stepwise regression including cisplatin dosage, initial Clcr, and cycle number (r=0.58, p<0.0001). CONCLUSION: We consider our results to be a first step toward a clinical strategy to identify patients at risk for renal dysfunction after cisplatin treatment.

Adult↗